Literature DB >> 10750057

Generalized treatment effects for clinical trials.

W W Hauck1, T Hyslop, S Anderson.   

Abstract

Practice in the analysis of clinical trials with continuously measured endpoints is to focus on the difference or percentage change in mean or median response. However, treatments may have effects on the distribution of responses other than on the average response. We sought an approach to such generalized treatment effects that: (i) targets a parameter that is easily understood by our clinical colleagues; and (ii) employs confidence intervals as the basis for inference. We consider one such approach based on work in reliability theory, namely setting Pr[Y>X] as the target parameter, and compare this approach to an earlier one due to O'Brien. The two approaches have similar properties when they both seek to reject the null hypothesis of no effect due to different variances but differ when the larger variance corresponds to the larger mean. In that case, our approach views that the larger variance attenuates the effect of the larger mean. Out suggested approach applies easily to positive control (clinical) equivalence trials. Copyright 2000 John Wiley & Sons, Ltd.

Mesh:

Year:  2000        PMID: 10750057     DOI: 10.1002/(sici)1097-0258(20000415)19:7<887::aid-sim388>3.0.co;2-l

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  3 in total

1.  Individual results may vary: Inequality-probability bounds for some health-outcome treatment effects.

Authors:  John Mullahy
Journal:  J Health Econ       Date:  2018-07-04       Impact factor: 3.883

2.  Evaluations and comparisons of treatment effects based on best combinations of biomarkers with applications to biomedical studies.

Authors:  Albert Vexler; Xiwei Chen; Jihnhee Yu
Journal:  J Comput Biol       Date:  2014-07-14       Impact factor: 1.479

3.  Phase II trial design with growth modulation index as the primary endpoint.

Authors:  Jianrong Wu; Li Chen; Jing Wei; Heidi Weiss; Rachel W Miller; John L Villano
Journal:  Pharm Stat       Date:  2018-11-20       Impact factor: 1.234

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.